BSX Stock Overview
Develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Boston Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$74.55 |
| 52 Week High | US$74.67 |
| 52 Week Low | US$48.35 |
| Beta | 0.77 |
| 1 Month Change | 9.44% |
| 3 Month Change | 13.26% |
| 1 Year Change | 39.50% |
| 3 Year Change | 77.84% |
| 5 Year Change | 97.27% |
| Change since IPO | 1,641.31% |
Recent News & Updates
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10
Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Recent updates
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate
May 21Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture
Apr 03Boston Scientific Stands Out With Strong, Diversified Growth Profile
Feb 15Boston Scientific Non-GAAP EPS of $0.45 misses by $0.02, revenue of $3.24B in-line
Feb 01Boston Scientific sees double digit EPS growth in 2023 - JPMorgan Healthcare conference
Jan 11Boston Scientific to acquire majority stake of Acotec Scientific
Dec 12Shareholder Returns
| BSX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.6% | 2.8% | 2.3% |
| 1Y | 39.5% | 2.0% | 26.8% |
Return vs Industry: BSX exceeded the US Medical Equipment industry which returned 2% over the past year.
Return vs Market: BSX exceeded the US Market which returned 26.8% over the past year.
Price Volatility
| BSX volatility | |
|---|---|
| BSX Average Weekly Movement | 2.7% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BSX has not had significant price volatility in the past 3 months.
Volatility Over Time: BSX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 48,000 | Mike Mahoney | www.bostonscientific.com |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Boston Scientific Corporation Fundamentals Summary
| BSX fundamental statistics | |
|---|---|
| Market cap | US$109.45b |
| Earnings (TTM) | US$1.76b |
| Revenue (TTM) | US$14.71b |
62.1x
P/E Ratio7.5x
P/S RatioIs BSX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSX income statement (TTM) | |
|---|---|
| Revenue | US$14.71b |
| Cost of Revenue | US$4.56b |
| Gross Profit | US$10.15b |
| Other Expenses | US$8.38b |
| Earnings | US$1.76b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.20 |
| Gross Margin | 69.00% |
| Net Profit Margin | 11.99% |
| Debt/Equity Ratio | 52.6% |
How did BSX perform over the long term?
See historical performance and comparison